A Malaysian consensus report on the diagnosis and treatment of Helicobacter pylori infection. Issue 4 (27th March 2023)

• Record Type: Journal Article
• Authors: Goh, Khean‐Lee; Lee, Yeong Yeh; Leow, Alex Hwong‐Ruey; Ali, Raja Affendi Raja; Ho, Shiaw Hooi; Mahadeva, Sanjiv; Mohd Said, Rosaida Hj; Muthukaruppan Chettiar, Raman; Tee, Hoi Poh
• Is Part Of: JGH open. Volume 7:Issue 4(2023)
• Page Start: 261
• Page End: 271
• Publication Date: 2023-03-27
• Subjects: diagnosis -- Helicobacter pylori infection -- Malaysian consensus -- peptic ulcer disease -- treatment
• DOI: 10.1002/jgh3.12886
• Languages: English
• ISSNs: 2397-9070

Abstract

Abstract: Helicobacter pylori is one of the most common chronic bacterial infections in humans and responsible for 90% of duodenal ulcers and 70–90% of gastric ulcers. Despite this, many misconceptions regarding the appropriate diagnostic method and treatment strategies still exist in the Malaysian clinical practice. Under the initiative of the steering committee, an expert panel consisting of nine key opinion leaders in the field of gastroenterology convened to develop a set of consensus statements that are relevant to the Malaysian healthcare practice. The panel members reviewed the current evidence on the management of H. pylori infection, focusing on the best practices that are relevant to the Malaysian population based on clinical experience and published clinical evidence. Using the modified Delphi method, the panel achieved consensus in three areas of H. pylori infection management: indications for testing, diagnosis, and treatment. The panel proposed a set of 19 consensus statements, which were synthesized via two rounds of blinded voting and group discussions. The recommendations provided are relevant to the Malaysian population and can be used as a guide by physicians across various healthcare settings to facilitate appropriate diagnostic testing and treatment of H. pylori infection. Abstract : The recommended first‐line therapy for H. pylori infection is a 2‐week standard triple therapy (STT) consisting of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin. For patients with penicillin allergy, a PPI‐clarithromycin‐metronidazole combination therapy is the preferred first‐line treatment. For patients who have failed the 2‐week STT, the recommended rescue therapy is a 2‐week high‐dose dual therapy.